Teaching an old dog new tricks: re-engineering IL-2 for immuno-oncology applications
Various approaches are being explored to address the unmet medical need among patients with advanced cancer who do not respond to immune checkpoint inhibitors. Interleukin-2 has become a prominent focus of preclinical and clinical investigation, because of its known clinical activity, the important...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827269/ https://www.ncbi.nlm.nih.gov/pubmed/36609489 http://dx.doi.org/10.1136/jitc-2022-006346 |